上海歌斐木生物医药科技

Gefeimu Biotech is a Shanghai-based biotechnology company specializing in the development of next-generation gene therapies. The company leverages its proprietary G-AAV platform to design optimized Adeno-associated virus (AAV) vectors with improved tissue targeting and reduced immunogenicity. Its primary focus areas include ophthalmology, central nervous system (CNS) disorders, and metabolic diseases. Gefeimu's lead programs, G-001 and G-002, are aimed at treating neovascular age-related macular degeneration and diabetic macular edema, respectively. The company aims to provide long-lasting therapeutic solutions through one-time administration of gene-based medicines.